Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Fulcrum Therapeutics ( (FULC) ) has provided an announcement.
Fulcrum Therapeutics announced that Genzyme Corporation, a Sanofi subsidiary, has chosen to terminate their collaboration and license agreement regarding the commercialization of losmapimod for facioscapulohumeral muscular dystrophy outside the United States. This termination, effective April 17, 2025, will halt milestone payments, royalties, and shared global development costs, impacting Fulcrum’s financial and operational expectations. Until then, both parties will continue fulfilling their obligations under the agreement.
More about Fulcrum Therapeutics
Fulcrum Therapeutics operates in the biotechnology industry, focusing on the development of treatments for genetically defined diseases. The company is primarily engaged in researching and commercializing small molecule therapies, with a particular focus on muscle disorders.
YTD Price Performance: -35.56%
Average Trading Volume: 1,005,350
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $234.6M
Find detailed analytics on FULC stock on TipRanks’ Stock Analysis page.
